Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$308.78
+0.3%
$271.78
$152.30
$310.22
$40.16B0.22931,893 shs520,199 shs
BioNTech SE stock logo
BNTX
BioNTech
$106.33
-0.2%
$101.37
$76.53
$131.49
$25.56B1.29948,108 shs1.24 million shs
Coloplast A/S stock logo
CLPBY
Coloplast A/S
$9.78
+0.2%
$10.06
$9.34
$14.14
N/A0.34210,841 shs968,846 shs
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
$92.15
+1.0%
$96.27
$89.22
$116.71
$18.06B0.721.79 million shs2.21 million shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
+0.26%+1.57%+8.23%+26.39%+92.52%
BioNTech SE stock logo
BNTX
BioNTech
-0.23%-2.42%+14.62%+7.45%+15.48%
Coloplast A/S stock logo
CLPBY
Coloplast A/S
+0.17%+2.24%+1.90%-7.85%-19.53%
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
+1.01%-0.75%-4.79%-18.29%-14.03%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
4.2459 of 5 stars
2.45.00.04.33.42.50.6
BioNTech SE stock logo
BNTX
BioNTech
2.8668 of 5 stars
4.43.00.00.02.50.80.0
Coloplast A/S stock logo
CLPBY
Coloplast A/S
N/AN/AN/AN/AN/AN/AN/AN/A
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
4.9181 of 5 stars
3.15.02.53.72.82.52.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2.77
Moderate Buy$319.583.50% Upside
BioNTech SE stock logo
BNTX
BioNTech
2.83
Moderate Buy$137.8629.65% Upside
Coloplast A/S stock logo
CLPBY
Coloplast A/S
2.40
HoldN/AN/A
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
2.29
Hold$111.5321.03% Upside

Current Analyst Ratings Breakdown

Latest CLPBY, BNTX, ALNY, and ZBH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/16/2025
BioNTech SE stock logo
BNTX
BioNTech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$145.00 ➝ $138.00
6/12/2025
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$330.00 ➝ $338.00
6/5/2025
BioNTech SE stock logo
BNTX
BioNTech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$134.00 ➝ $145.00
6/3/2025
BioNTech SE stock logo
BNTX
BioNTech
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$151.00 ➝ $155.00
6/2/2025
BioNTech SE stock logo
BNTX
BioNTech
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$112.00
5/29/2025
BioNTech SE stock logo
BNTX
BioNTech
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy ➝ Neutral$110.00
5/22/2025
BioNTech SE stock logo
BNTX
BioNTech
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$120.00 ➝ $116.00
5/22/2025
BioNTech SE stock logo
BNTX
BioNTech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$134.00 ➝ $134.00
5/14/2025
BioNTech SE stock logo
BNTX
BioNTech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$145.00 ➝ $134.00
5/12/2025
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$115.00 ➝ $101.00
5/9/2025
Coloplast A/S stock logo
CLPBY
Coloplast A/S
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeModerate Buy ➝ Hold
(Data available from 6/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$2.35B17.15N/AN/A$0.52 per share593.81
BioNTech SE stock logo
BNTX
BioNTech
$2.75B9.31$4.57 per share23.25$92.17 per share1.15
Coloplast A/S stock logo
CLPBY
Coloplast A/S
$3.93BN/AN/AN/AN/AN/A
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
$7.70B2.37$11.74 per share7.85$62.67 per share1.47
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
-$278.16M-$2.09N/A346.94N/A-12.37%N/A-6.83%7/30/2025 (Estimated)
BioNTech SE stock logo
BNTX
BioNTech
$1.01B-$3.40N/AN/AN/A-15.16%-2.35%-2.05%8/4/2025 (Estimated)
Coloplast A/S stock logo
CLPBY
Coloplast A/S
$734.56M$0.3030.5524.443.0817.81%28.60%10.01%8/19/2025 (Estimated)
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
$903.70M$4.5220.7110.391.9511.77%12.99%7.58%8/6/2025 (Estimated)

Latest CLPBY, BNTX, ALNY, and ZBH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2025Q2 2025
Coloplast A/S stock logo
CLPBY
Coloplast A/S
$0.0874$0.06-$0.0274$0.06$7.02 billion$1.05 billion
5/5/2025Q1 2025
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
$1.77$1.81+$0.04$0.91$1.89 billion$1.91 billion
5/1/2025Q1 2025
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
-$0.37-$0.44-$0.07-$0.44$584.32 million$594.19 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
N/AN/AN/AN/AN/A
BioNTech SE stock logo
BNTX
BioNTech
$1.531.44%N/AN/A N/A
Coloplast A/S stock logo
CLPBY
Coloplast A/S
$0.080.82%N/A26.67%N/A
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
$0.961.04%N/A21.24%N/A

Latest CLPBY, BNTX, ALNY, and ZBH Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/30/2025
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
quarterly$0.241.03%6/26/20256/26/20257/31/2025
5/16/2025
Coloplast A/S stock logo
CLPBY
Coloplast A/S
$0.03892.02%5/16/20255/19/20255/22/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
15.27
2.78
2.71
BioNTech SE stock logo
BNTX
BioNTech
0.01
7.33
7.21
Coloplast A/S stock logo
CLPBY
Coloplast A/S
0.92
1.02
0.66
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
0.43
1.91
0.99

Institutional Ownership

CompanyInstitutional Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
92.97%
BioNTech SE stock logo
BNTX
BioNTech
15.52%
Coloplast A/S stock logo
CLPBY
Coloplast A/S
N/A
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
88.89%

Insider Ownership

CompanyInsider Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
1.50%
BioNTech SE stock logo
BNTX
BioNTech
19.20%
Coloplast A/S stock logo
CLPBY
Coloplast A/S
N/A
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
1.39%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2,000130.39 million127.52 millionOptionable
BioNTech SE stock logo
BNTX
BioNTech
3,080240.39 million193.71 millionOptionable
Coloplast A/S stock logo
CLPBY
Coloplast A/S
16,875N/AN/ANot Optionable
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
18,000197.85 million197.18 millionOptionable

Recent News About These Companies

Zimmer Biomet seeks a ZBEdge for its Rosa robotic surgery

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alnylam Pharmaceuticals stock logo

Alnylam Pharmaceuticals NASDAQ:ALNY

$308.78 +0.79 (+0.26%)
Closing price 06/16/2025 04:00 PM Eastern
Extended Trading
$308.92 +0.14 (+0.04%)
As of 06/16/2025 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

BioNTech stock logo

BioNTech NASDAQ:BNTX

$106.33 -0.24 (-0.23%)
Closing price 06/16/2025 04:00 PM Eastern
Extended Trading
$106.10 -0.22 (-0.21%)
As of 04:26 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Coloplast A/S stock logo

Coloplast A/S OTCMKTS:CLPBY

$9.78 +0.02 (+0.17%)
As of 06/16/2025 03:59 PM Eastern

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.

Zimmer Biomet stock logo

Zimmer Biomet NYSE:ZBH

$92.15 +0.87 (+0.95%)
Closing price 06/16/2025 03:59 PM Eastern
Extended Trading
$92.27 +0.12 (+0.13%)
As of 06/16/2025 07:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.